000990 Chengzhi Co.,Ltd.
- 7.95
- -0.02-0.25%
Chengzhi Co.,Ltd. News
Chengzhi Co., Ltd. (000990.SZ): Specializing in the production and operation of various industrial gases such as hydrogen, carbon monoxide and synthetic gas
Gelonghui, May 27丨Chengzhi Co., Ltd. (000990.SZ) said on the investor interactive platform that the company is a leading comprehensive operator of industrial gases and basic chemical raw materials in the field of clean energy in China. It specializes in the production and operation of various industrial gases such as hydrogen, carbon monoxide and synthetic gas, and co-produces chemical products such as methanol, ethylene, propylene, and butyl octanol.
Chengzhi Co., Ltd. (000990.SZ): There are technical reserves for hyaluronic acid production, but production has not yet been arranged
Gelonghui, May 23 | Chengzhi Co., Ltd. (000990.SZ) said on the investor interactive platform that the company has technical reserves for hyaluronic acid production but has not yet arranged production. In the future, the company will continue to implement the “two wings in one” strategy, actively promote the implementation of strategic goals and tasks, and make steady progress in the advanced direction of high-end new chemical materials, advanced semiconductor display materials, synthetic biology, etc., to further strengthen the company's existing resource allocation and form a better industrial cluster effect.
Chengzhi Co., Ltd. (000990.SZ) plans to pay 0.5 yuan for 10 shares to be deducted from interest on May 29
Chengzhi Co., Ltd. (000990.SZ) announced that the company's 2023 equity distribution plan: to all shareholders for every 10...
Chengzhi Co., Ltd. (000990.SZ): Products in the field of synthetic biology are mainly used in the fields of food, nutritional supplements, pharmaceutical raw materials, pharmaceutical intermediates, etc.
Gelonghui, May 21丨Chengzhi Co., Ltd. (000990.SZ) said on the investor interactive platform that the company's products in the field of synthetic biology are mainly used in the fields of food, nutritional supplements, pharmaceutical raw materials, pharmaceutical intermediates, etc. Among them, the company dominates the international market in the field of D-ribose products, and is an innovative multinational enterprise that also has complete intellectual property rights for the manufacture and application of D-ribose products; D-mannose developed by the company was also mass-produced in 2023, and product sales are growing steadily.
Chengzhi Co., Ltd. (000990.SZ): D-ribose can be used as a starting ingredient for certain COVID-19 drugs
Gelonghui May 13 丨 Some investors asked Chengzhi Co., Ltd. (000990.SZ) on the investor interactive platform, “Can the company's products be used for COVID-19 drugs?” The company replied that the company's D-ribose can be used as a starting ingredient for certain COVID-19 drugs.
Chengzhi Co., Ltd.'s (SZSE:000990) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 0.9x Chengzhi Co., Ltd. (SZSE:000990) is a stock worth checking out, seeing as almost half of all the Chemicals companies in China have P/S
Chengzhi Co., Ltd. (000990.SZ): The synthetic biology business is one of the company's main businesses in the biomedical sector
Gelonghui, May 9 | Chengzhi Co., Ltd. (000990.SZ) said on the investor interactive platform that the synthetic biology business is one of the company's main businesses in the biomedical sector. Among them, production and sales of the company's D-ribose series products have grown rapidly in recent years. Currently, they dominate the global market and are widely used in medicine, nutrition and health care, food and beverage, clinical nutrition, etc. D-mannose developed by the company was mass-produced in 2023, and product sales have been growing steadily.
Chengzhi Co., Ltd. (000990.SZ): A new enzyme independently developed using synthetic biology technology has completed strain construction and the development of a new process for enzyme conversion, and is currently undergoing testing
Gelonghui, May 9 | Chengzhi Co., Ltd. (000990.SZ) said on the investor interactive platform that the company has independently developed a new enzyme using synthetic biology technology that has completed strain construction and the development of a new process for enzyme conversion. It is currently undergoing testing and certification, and has applied for a number of patents. In 2023, the company cooperated with Academician Tan Tianwei's team to establish the “Chengzhi Co., Ltd. - Beijing University of Chemical Technology Joint Engineering Research and Transformation Center” to carry out in-depth cooperation in strain construction and enzyme modification, process optimization and technology iteration, incubation of innovative achievements, etc., to continuously enrich product categories and promote the company's high-quality development. The future, the company
Chengzhi (SZSE:000990) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Chengzhi Co., Ltd. (000990.SZ): Overseas business is mainly TFT LCD products, D-ribose and other products
Gelonghui, April 18, 丨 Chengzhi Co., Ltd. (000990.SZ) held a performance briefing on April 17, 2024. Regarding “Can you talk about the development of the company's overseas business, the intensification of domestic competition, and whether overseas business expansion will increase”, the company replied that the company's overseas business is mainly products such as TFT LCD products and D-ribose, and the market sales of these products are good. In the future, dynamic adjustments will be made according to domestic and foreign market conditions.
Chengzhi Co., Ltd. (000990.SZ) announced first-quarter results, net profit of 154 million yuan, reversing year-on-year losses
Chengzhi Co., Ltd. (000990.SZ) released its report for the first quarter of 2024, achieving operating income of 27 during the reporting period...
Chengzhi Co., Ltd. (000990.SZ): POE downstream consumption structure includes TPO terminals, polymer modifications, wires and cables, etc.
Gelonghui, April 11 | Chengzhi Co., Ltd. (000990.SZ) said on the investor interactive platform that the POE downstream consumption structure includes TPO terminals, polymer modifications, wires and cables, etc.
Chengzhi Acquires Liquid Crystal Material Patent From DIC for 4.97 Billion Yen
Chengzhi (SHE:000990) agreed to acquire 1,183 liquid crystal material patent from Japan's DIC for 4.97 billion Japanese yen, according to the company's disclosure on the Shenzhen Stock Exchange. The p
Chengzhi Co., Ltd. (000990.SZ): Chengzhi Innovation plans to participate in the subscription for a fund share of 100 million yuan from Qingdao Chuxin
On March 21, Ge Longhui Co., Ltd. (000990.SZ) announced that the company's wholly-owned subsidiary, Beijing Chengzhi Technology Innovation Development Co., Ltd. (“Chengzhi Innovation”), plans to subscribe for a fund share of 100 million yuan from Qingdao Chuxin Haiping Equity Investment Fund Partnership (Limited Partnership) (“Qingdao Chuxin” or “Fund” for short) in order to continuously improve profitability and accelerate its layout in the semiconductor field. Qingdao Chuxin is a limited partnership established in accordance with law. The fund size is 1 billion yuan. The fund is managed by Qingdao Xinping Investment Management Co., Ltd. (“Qingdao Xinping” for short). The main investors in the fund
Chengzhi's (SZSE:000990) Solid Earnings Are Supported By Other Strong Factors
Chengzhi Co., Ltd. (SZSE:000990) just reported healthy earnings but the stock price didn't move much. Investors are probably missing some underlying factors which are encouraging for the future of th
Chengzhi Co., Ltd. (000990.SZ): The subsidiary Nanjing Chengzhi produces hydrogen mainly for use by surrounding supporting companies
Gelonghui March 13 丨 Some investors asked Chengzhi Co., Ltd. (000990.SZ) on the investor interactive platform, “What are your company's main hydrogen sales areas?” The company replied that the hydrogen produced by its subsidiary Nanjing Chengzhi is mainly used by surrounding supporting companies, and that surplus hydrogen will be used for the operation and use of hydrogen refueling stations.
Chengzhi Co., Ltd. (000990.SZ): 2023 net profit of 177 million yuan increased 248.36% year-on-year
On March 12, Ge Longhui Co., Ltd. (000990.SZ) released its 2023 annual report. Operating income was 12.417 billion yuan, up 5.97% year on year, net profit of 177 million yuan, up 248.36% year on year, after deducting non-net profit of 152 million yuan, up 671.90% year on year, with basic earnings per share of 0.1,460 yuan.
Chengzhi Co., Ltd. (000990.SZ): The subsidiary plans to participate in the establishment of Qingdao Dingrong Xinxing Private Equity Fund
Gelonghui, March 12, 丨 Chengzhi Co., Ltd. (000990.SZ) announced that its wholly-owned subsidiary Beijing Chengzhi Technology Innovation Development Co., Ltd. intends to participate as a limited partner in the establishment of the Qingdao Dingrong Xinxing Private Equity Investment Fund Partnership (limited partnership) (“Dingrong Emerging Fund”). The total target size of Dingrong Emerging Fund is no more than 700 million yuan, and the initial scale is no more than 230 million yuan. The limited partners entered in batches during the fundraising period and completed pledges of the corresponding scale. As a limited partner, Chengzhi Innovation plans to pledge an investment of RMB 98 million, accounting for no less than 14.00% of the total scale mentioned above. Among them, the first
Chengzhi Co., Ltd. (000990.SZ): The main products are nutritional supplement products such as D-ribose, libose, probiotics, etc.
On March 7, Ge Longhui Co., Ltd. (000990.SZ) said on the investor interactive platform that in the biomedical field, as the only company in the world with complete intellectual property rights for D-ribose, the company has actively invested in development for more than 20 years. Its main products are nutritional supplement products such as D-ribose, Levos, and probiotics. The company will continue to explore the D-ribose market, increase its market share, accelerate the construction of multi-purpose workshops and API workshop projects, further expand the diversification of product structures, keep up with cutting-edge synthetic biology research, focus on the big health industry, and deepen the large-scale development of the company's bio-manufacturing materials sector.
Little Excitement Around Chengzhi Co., Ltd.'s (SZSE:000990) Revenues As Shares Take 28% Pounding
The Chengzhi Co., Ltd. (SZSE:000990) share price has fared very poorly over the last month, falling by a substantial 28%. Instead of being rewarded, shareholders who have already held through the l
Analysis
Price Target
No Data
